ACADIA Pharmaceuticals Inc.
ACAD
Hisse Senetlerindeki Sıralama
#4461
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Hisse Fiyatı
$20.27
Piyasa Değeri
$3.49B
Değişim (1 gün)
2.35%
Değişim (1 yıl)
-3.22%
Ülke
US
Ticaret ACADIA Pharmaceuticals Inc. (ACAD)
Kategori
Healthcare
ACADIA Pharmaceuticals Inc. (ACAD) için tedavüldeki hisse sayısı
June 2026 itibarıyla tedavüldeki hisse sayısı: 171.60M
ACADIA Pharmaceuticals Inc. şirketinin son finansal raporlarına ve hisse fiyatına göre, mevcut tedavüldeki hisse sayısı 171.60M'dir. December 2023 sonunda şirketin 163.82M tedavüldeki hissesi vardı. Tedavüldeki hisse sayısı genellikle hisse bölünmeleri ve hisse geri alımları ile etkilenir.
ACADIA Pharmaceuticals Inc. (ACAD) için 2000 - 2026 tarihleri arasındaki hisse geçmişi
Her yıl sonunda tedavüldeki hisse sayısı
| Yıl | Tedavüldeki Hisse Sayısı | Değiştir |
|---|---|---|
| 2026 (TTM) | 171.60M | 3.55% |
| 2024 | 165.72M | 1.16% |
| 2023 | 163.82M | 1.32% |
| 2022 | 161.68M | 0.74% |
| 2021 | 160.49M | 2.01% |
| 2020 | 157.33M | 6.88% |
| 2019 | 147.20M | 16.29% |
| 2018 | 126.58M | 3.25% |
| 2017 | 122.60M | 5.82% |
| 2016 | 115.86M | 15.13% |
| 2015 | 100.63M | 3.48% |
| 2014 | 97.25M | 13.46% |
| 2013 | 85.72M | 56.23% |
| 2012 | 54.87M | 5.14% |
| 2011 | 52.18M | 35.21% |
| 2010 | 38.59M | 2.98% |
| 2009 | 37.48M | 0.98% |
| 2008 | 37.11M | 5.40% |
| 2007 | 35.21M | 26.10% |
| 2006 | 27.92M | 26.84% |
| 2005 | 22.01M | 112.63% |
| 2004 | 10.35M | 609.62% |
| 2003 | 1.46M | 0.48% |
| 2002 | 1.45M | 20.20% |
| 2001 | 1.21M | 12.90% |
| 2000 | 1.07M | 0.00% |
Benzer şirketler veya rakipler için tedavüldeki hisse sayısı
| Şirket | Tedavüldeki Hisse Sayısı | Fark | Ülke |
|---|---|---|---|
| 253.90M | 47.96% |
US
|
|
| 396.00M | 130.77% |
US
|
|
| 478.91M | 179.08% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -63.76% |
NL
|
